Skip to content
Screener

Immunome IMNM Q2 2025 earnings

Reported August 6, 2025 · Before market open

Revenue$4.0MBeat by $3.2M
EPS-$0.50Beat by $0.02
Revenue estimate$833.3K
EPS estimate-$0.52

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$181.8K
EPS estimate-$0.64

Financials

Q2 2025

Income statement

See full
Revenue$4.0M+69.8%
Operating income-$46.5M-16.2%
Net income-$43.4M-20.1%
EPS (diluted)-$0.50+16.7%

Balance sheet

See full
Cash & equivalents$143.9M-13.0%
Total debt$4.1M+49.4%
Total equity$269.3M+6.1%
Total assets$296.3M0.0%

Cash flow

See full
Operating cash flow-$49.4M-111%
CapEx$905.0K-61.4%
Free cash flow-$50.3M-95.4%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$776.15M+7.0%
Enterprise value$636.42M+13.0%
P/S61.7×-5.6×

Profitability

See full
Operating margin-1,784.1%-403pp
Net margin-1,687.1%-396pp
FCF margin-1,476.8%—

Returns & leverage

See full
Return on equity-81.2%-30.2pp
Debt / equity0×0.0×
Current ratio12.1×+5.0×

FAQ

When did Immunome report Q2 2025 earnings?
Immunome (IMNM) reported Q2 2025 earnings on August 6, 2025 before market open.
What were Immunome's Q2 2025 revenue and EPS?
Immunome reported revenue of $4.0M and eps of $-0.50 for Q2 2025.
Did Immunome beat estimates in Q2 2025?
Revenue beat the consensus estimate of $833.3K by $3.2M. EPS beat the consensus estimate of $-0.52 by $0.02.
How did Immunome's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 69.8% from $2.4M a year earlier and eps declined 2.0% from $-0.49.
Where can I find Immunome's Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-104015) and the 10-Q periodic report (0000950170-25-104035) directly on SEC EDGAR. The filing index links above go to sec.gov.